Hematopoietic stem cell transplantation (HSCT) has become a cornerstone in the management of various haematological malignancies and non-malignant disorders. Central to this therapeutic approach is ...
Localized Pelvic Neuroblastoma: Excellent Survival and Low Morbidity With Tailored Therapy—The 10-Year Experience of the French Society of Pediatric Oncology We recently reported that children with ...
Donor lymphocyte infusion, both alone and in combination with azacitidine, restored CD34 levels in two-thirds of patients with a baseline CD34 donor chimerism of less than 80%. Researchers confirmed ...
AlloHeme test accurately predicts relapse post-allo-HSCT in AML and MDS, with a median lead time of 36 days. The ACROBAT study involved 287 patients, showing significant predictive value of increased ...
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. As a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback